Basic research on improvement of alveolar barrier function using adipose stem cells and novel cell therapy for ALI/ARDS

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08907
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55040:Respiratory surgery-related
• Research Institution: Nagasaki University
• Principal Investigator: Ishii Mitsutoshi 長崎大学, 医歯薬学総合研究科(医学系), 客員研究員 (60783066)
• Co-Investigator(Kenkyū-buntansha): 宮崎 拓郎 長崎大学, 病院(医学系), 講師 (00584749) ; 土谷 智史 長崎大学, 医歯薬学総合研究科(医学系), 客員教授 (30437884) ; 永安 武 長崎大学, 医歯薬学総合研究科(医学系), 教授 (80284686) ; 佐原 寿史 鹿児島大学, 総合科学域総合研究学系, 准教授 (90452333)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 呼吸器再生 / 幹細胞治療 / 肺胞バリア機能 / 急性肺障害 / 慢性閉塞性肺疾患

Outline of Final Research Achievements

In this study, we investigated the therapeutic effect of mesenchymal stem cell (MSC) administration on chronic obstructive pulmonary disease (COPD), one of the basic respiratory diseases, and found that MSCs administered intravenously in a COPD mouse model grew in the lungs for a longer period than normal cultured cells and suppressed tissue damage through anti-inflammatory and immunosuppressive actions. The results showed that intravenous administration of MSCs in COPD model mice suppressed tissue damage through anti-inflammatory and immunosuppressive effects. Furthermore, MSCs showed highly efficient induction of differentiation into pulmonary capillary endothelial cells and myofibroblasts in the lung tissue, confirming their remarkable efficacy. Flow cytometric analysis of lung tissue after cell administration showed that macrophages in the cell administration group showed a change in polarity to M2 macrophages, suggesting their involvement in tissue repair.

Free Research Field

呼吸器外科学

Academic Significance and Societal Importance of the Research Achievements

ALI/ARDSへの細胞治療としてADSCによる細胞治療の有効性の基礎的データを得るための開始の研究として重要であり、特にADSCによる肺のバリア機能の強化を目的とした、未だ行われていない研究である。今後、ブタ肺虚血再灌流モデルでALI/ARDSを誘発し、ADSC静脈投与の有用性、安全性を証明することによって、ALI/ARDSの新たな治療選択肢としてADSCの細胞治療を確立できる。